Matinas BioPharma remains a pre-revenue clinical-stage entity, with its fundamental outlook entirely dependent on the successful advancement of its Lipid Nanocrystal platform. The company faces significant existential risk as it navigates a period of rapid ass...
Price trend, volume and key moving averages
Trailing total returns as of 10/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 8, 2026 | -$0.30+77.2% vs -$1.32 | — vs $25,000 |
Q2 2026 Mar 31, 2026 | -$0.30+77.2% vs -$1.32 | — vs $25,000 |
Q4 2025 Nov 10, 2025 | -$0.40 vs — | — vs — |
Q3 2025 Aug 14, 2025 | -$1.03 vs — | — vs — |
Agreement establishes GH Power's first commercial hydrogen offtake and validates hydrogen production from the Company's proprietary aluminum-water reactor platform Agreement establishes GH Power's first commercial hydrogen offtake and validates hydrogen production from the Company's proprietary aluminum-water reactor platform
BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on August 31, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years.
Benchmark MTNB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Matinas BioPharma Holdings, Inc. (MTNB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.71 | $730.3K | -0.06 | — | — | -166.59% | — | |
| $31.20 | $3.9B | -240.00 | 91.34% | 6.15% | 15.05% | — | |
| $37.22 | $1.23B | -3.83 | -43.89% | -287.84% | -37.99% | — | |
| $252.96 | $7.05B | -18.77 | -100% | — | -34.15% | — | |
| $156.04 | $193.73B | 23.01 | 2.39% | -10.64% | -16.35% | — | |
| $60.59 | $5.03B | 7.79 | 114.51% | -3.8% | — | — |
Matinas BioPharma Holdings, Inc. (MTNB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Matinas BioPharma Holdings, Inc. (MTNB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 24, 2026·SEC
Jul 13, 2026·SEC
Jun 26, 2026·SEC
Get notified when MTNB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Matinas BioPharma Holdings, Inc. (MTNB) stock FAQ — growth, dividends, profitability & financials explained
Matinas BioPharma Holdings, Inc. (MTNB) reported a net loss of $7.3M for fiscal year 2025.
Matinas BioPharma Holdings, Inc. (MTNB) has a return on equity (ROE) of -166.6%. Negative ROE indicates the company is unprofitable.
Matinas BioPharma Holdings, Inc. (MTNB) had negative free cash flow of $6.4M in fiscal year 2025, likely due to heavy capital investments.
